For Investors: Confidence
The scenario for investors:
- Little technical risk
- Commercial Risk
- The technical risk has been eliminated or reduced to a very small level by taking products already close to or having marketing approval in North America and/or Europe.
The development risk in Asia is limited since most pharmaceutical products have already been studied in Asiatic populations in the global development programs for North America and/or Europe.
What remains is the commercial risk in Asia. Our internal resource leads the Asian P&L production document we deliver to potential investors.
The choice of which type of product to bring into the SingEval portfolio can include :
- Pharmaceutical : new chemical entities
- New formulations with same indication as original product, eg long acting
- New formulations with different indications
- Devices
- Diagnostics
Each choice carries different investment costs, time, sales curve projections, milestone or royalty payments and ROI. The ability to make choices on funding meets investor needs at any time in their relationship with SingEval.